Literature DB >> 6639890

The effects of alpha-thalassaemia in HbSC disease.

M H Steinberg, M B Coleman, J G Adams, O Platica, P Gillette, R F Rieder.   

Abstract

In HbSC disease, as in sickle cell anaemia, there is a spectrum of clinical severity. A reduced mean corpuscular volume and haemoglobin concentration, traits typical of thalassaemia, might retard sickling. We therefore ascertained the prevalence of alpha-thalassaemia in 53 adults with HbSC disease and related alpha-globin gene deletion to the haematologic and clinical findings. Alpha-globin genotype was identified by restriction endonuclease gene mapping. Indirect ophthalmoscopy and fluorescein angiography were used to document the presence of proliferative retinopathy. Bone necrosis and infarction were determined roentgenographically or by radionuclide scanning. Either heterozygous or homozygous alpha-thalassaemia-2 was present in 26% of patients. There was no relationship between alpha-globin genotype and haematocrit, pain crises, bone lesions, proliferation retinopathy or clinical severity score.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6639890     DOI: 10.1111/j.1365-2141.1983.tb02164.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

1.  Concurrent sickle cell hemoglobin C disease and diabetes mellitus: no added risk of proliferative retinopathy?

Authors:  P R Koduri; A R Patel; H A Bernstein
Journal:  J Natl Med Assoc       Date:  1994-09       Impact factor: 1.798

2.  The pleiotropic effects of α-thalassemia on HbSS and HbSC sickle cell disease: Reduced erythrocyte cation co-transport activity, serum erythropoietin, and transfusion burden, do not translate into increased survival.

Authors:  John N Brewin; Amina Nardo-Marino; Sara Stuart-Smith; Sara El Hoss; Anke Hanneman; John Strouboulis; Stephan Menzel; John S Gibson; David C Rees
Journal:  Am J Hematol       Date:  2022-07-18       Impact factor: 13.265

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.